These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 11546946)

  • 1. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.
    Gallego O; de Mendoza C; Pérez-Elías MJ; Guardiola JM; Pedreira J; Dalmau D; Gónzalez J; Moreno A; Arribas JR; Rubio A; García-Arata I; Leal M; Domingo P; Soriano V
    AIDS; 2001 Sep; 15(13):1701-6. PubMed ID: 11546946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure.
    González de Requena D; Gallego O; de Mendoza C; Corral A; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2003 Jun; 19(6):457-9. PubMed ID: 12882654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
    Vray M; Meynard JL; Dalban C; Morand-Joubert L; Clavel F; Brun-Vézinet F; Peytavin G; Costagliola D; Girard PM;
    Antivir Ther; 2003 Oct; 8(5):427-34. PubMed ID: 14640390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice.
    Romano L; Venturi G; Giomi S; Pippi L; Valensin PE; Zazzi M
    J Med Virol; 2002 Feb; 66(2):143-50. PubMed ID: 11782921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].
    Manfredi R; Calza L
    Infez Med; 2002 Sep; 10(3):151-6. PubMed ID: 12704265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.
    Puig T; Pérez-Olmeda M; Rubio A; Ruiz L; Briones C; Franco JM; Gómez-Cano M; Stuyver L; Zamora L; Alvarez C; Leal M; Clotet B; Soriano V
    AIDS; 2000 Apr; 14(6):727-32. PubMed ID: 10807196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
    Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
    AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final analysis of the Trilège induction-maintenance trial: results at 18 months.
    Flandre P; Raffi F; Descamps D; Calvez V; Peytavin G; Meiffredy V; Harel M; Hazebrouck S; Pialoux G; Aboulker JP; Brun Vezinet F
    AIDS; 2002 Mar; 16(4):561-8. PubMed ID: 11872999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
    Havlir DV; Hellmann NS; Petropoulos CJ; Whitcomb JM; Collier AC; Hirsch MS; Tebas P; Sommadossi JP; Richman DD
    JAMA; 2000 Jan; 283(2):229-34. PubMed ID: 10634339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.
    Ruiz L; Nijhuis M; Boucher C; Puig T; Bonjoch A; Martínez-Picado J; Marfil S; de Jong D; Burger D; Arnó A; Balagué M; Clotet B
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):19-28. PubMed ID: 9732064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran.
    Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
    Descamps D; Joly V; Flandre P; Peytavin G; Meiffrédy V; Delarue S; Lastère S; Aboulker JP; Yeni P; Brun-Vézinet F
    J Clin Virol; 2005 Jun; 33(2):99-103. PubMed ID: 15911424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.